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Second-Generation
Everolimus-Eluting Stents
And the Beat Goes On?*
Michael A. Kutcher, MD
Winston-Salem, North Carolina
The past decade has seen a tremendous evolution in
percutaneous coronary intervention (PCI) stent technology
(1). The superiority of the first generation of drug-eluting
stents (DES) over bare-metal stents (BMS) to reduce
restenosis and repeat revascularization was demonstrated
with sirolimus-eluting stents (SES) (2) and with paclitaxel-
eluting stents (PES) (3). Once approved by the U.S. Food
and Drug Administration in 2003, there was unbridled
enthusiasm to use DES in increasingly complex lesion and
patient subsets. This strategy was subsequently tempered by
reports of late stent thrombosis (4) that led to major
concerns and a dramatic pullback in the use of DES. A
subsequent meta-analysis by Kirtane et al. (5) of random-
ized multicenter trials and registry data demonstrated the
safety and efficacy of DES versus BMS. Nevertheless,
lingering worries regarding cost, no clear mortality benefit,
and late stent thrombosis continued to affect the use of
DES.
See page 1209
To address these clinical issues, potential problems, such
as thicker stent struts, inflammation-inducing release poly-
mers, and the mechanisms of antiproliferative agents,
prompted the development of second-generation thinner
stent architecture and improved polymer and elution dy-
namics. One such effort has culminated in the current
second-generation everolimus-eluting stent (EES), Xience
V (Abbott Vascular, Santa Clara, California), also distrib-
uted as Promus (Boston Scientific, Natick, Massachusetts).
This stent architecture was compared with a PES, Taxus
Express in the SPIRIT (Clinical Evaluation of the Xience V
Everolimus Eluting Coronary Stent System in the Treat-
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Lesions) II (6), III (7), and IV (8) multicenter randomized
trials and the Taxus Liberte (Boston Scientific) in the
COMPARE (Comparison of the Everolimus Eluting
XIENCE-V Stent with the Paclitaxel Eluting TAXUS
LIBERTE Stent in All-Comers: a Randomized Open
Label Trial) (9). A recent meta-analysis of these 4 trials
demonstrated a significant reduction in target lesion
revascularization (TLR), myocardial infarction (MI), and
stent thrombosis in EES compared with PES at 1-year
follow-up (10).
There is great interest in the interventional cardiology
community as to the safety and effectiveness of second-
generation DES. Foremost is the issue of whether these
newer designs translate into a meaningful improvement in
long-term outcomes when compared with older first-
generation elution platforms, particularly in complex lesions
and off-label indications found in contemporary practice.
The study by Claessen et al. (11), in this issue of JACC:
ardiovascular Interventions, is a patient-level data analysis
ooled from the randomized SPIRIT II, III, IV, and
OMPARE trials to investigate the impact of reference
essel diameter (RVD) and lesion length (LL) on the
elative safety and efficacy of EES compared with PES.
uantitative angiographic core data were available in 6,183
atients randomized to EES (n  3,944) or PES (n 
,239). Long lesions were defined as LL  median (13.4
mm) and small vessels as RVDmedian (2.65 mm). Major
adverse cardiac events (MACE) assessed at 2 years included:
cardiac death, MI, or ischemia-driven TLR. Outcomes
according to stent type were analyzed in 3 groups: Group A
(n  1,297): short lesions in large vessels; Group B (n 
2,981): long lesions or small vessels, but not both; and
Group C (n  1,905): long lesions in small vessels.
The authors reported 2-year MACE rates of 5.6% in
Group A, 8.2% in Group B, and 10.4% in Group C. Group
A 2-year MACE rates were not significantly different
between EES (4.8%) and PES (7.0%). However, EES was
associated with lower 2-year rates of MACE in Group B
(6.6% vs. 11.2%, p  0.01) and in Group C (9.1% vs.
12.7%, p  0.008), as well as lower individual rates of MI
and TLR. Of note, stent thrombosis was significantly lower
in EES versus PES in the more complex groups—Group B
(0.5% vs. 1.4%, p  0.005) and Group C (0.3% vs. 1.9%,
p 0.0007). Cardiac mortality was also reduced in the EES
arm of Group B (1.0% vs. 2.1%, p  0.03). Multivariable
analysis confirmed EES versus PES was an independent
predictor of freedom from MACE in Groups B and C.
The investigators reaffirmed that, even in the DES era,
longer lesions and smaller vessel diameter continue to be
important determinants of long-term outcomes. However,
they concluded that in these more complex patients—those
with intermediate risk (long lesions or small vessels but not
both) and high risk (long lesions in small vessels)—second-
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1217generation EES appeared to be safer and more effective than
first-generation PES. The authors suggest a mechanism
may be attributable to the thin struts and a nonthrombo-
genic fluoropolymer on the EES surface.
So the “beat goes on” about the superiority of EES—or
does it? This study demonstrated that the outcomes were
similar in the low-risk group of short lesions in large vessels
regardless of the generation of stent used. One could
extrapolate that any type of DES or even BMS may do just
as well in this low-risk group. Even though the pooled
analysis was superbly done, the bulk of patients were from
the relatively selective SPIRIT trial patients (6–8). Only the
COMPARE study (9) was a “real-world” contemporary
study. Finally, diabetic patients were not extensively ana-
lyzed except for inclusion in the Cox model. The SPIRIT
IV study (8) and a post hoc analysis of the COMPARE
study (9) demonstrated similar results for EES and PES in
diabetic patients.
This is not a “home run” for use of second-generation
EES in extremely complex lesions and presentations. How-
ever, the investigators do contribute important information
on the safety and effectiveness of EES when patients are
stratified into higher-risk long lesion and small vessel size
subgroups.
The selection of EES for complex lesions in contempo-
rary clinical practice may be a foregone conclusion because
of dwindling alternatives in the United States. Johnson &
Johnson recently announced the discontinuation of the
Cypher SES (Cordis, Miami Lakes, Florida) and have
halted further development of the next-generation Nevo
SES platform (12). In addition, there is a lack of evidence
for any superiority benefits for the first-generation PES
compared with other DES (13) and a growing disenchant-
ment in the interventional cardiology community with this
elution scheme. So, in the “real world” of off-label use in
complex patients and lesions, at least in the United States,
the beat goes on for second-generation EES. Nevertheless,
subanalysis of multicenter data, as was nicely done by
Claessen et al. (11), and long-term post-marketing registries
should continue to be used to monitor the appropriate use of
EES in expanded complex clinical indications.
Although the beat goes on, lurking in the wings is a
newer third generation of DES architecture. However,
these newer stent platforms and elution schemes will have to
be compared to the ongoing and extensive accumulated
body of data regarding the clinical use of EES.Reprint requests and correspondence: Dr. Michael A. Kutcher,
Department of Internal Medicine (Cardiology), Wake Forest School
of Medicine, 1 Medical Center Boulevard, Winston-Salem, North
Carolina 27157-1045. E-mail: mkutcher@wakehealth.edu.
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